



Seres Therapeutics to Announce Third Quarter 2023 Results on Thursday, November 2, 2023; Host Conference Call and Webcast at 8:00 a.m. EST

October 30, 2023

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 30, 2023-- [Seres Therapeutics, Inc.](#) (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it will release third quarter 2023 financial results on Thursday, November 2, 2023. Management will host a conference call with investors to discuss the results and corporate updates at 8:00 a.m. ET.

The conference call may be accessed by calling 1-866-777-2509 (international callers dial 1-412-317-5413). Participants may pre-register for the conference call at <https://dpregrister.com/sreg/10184132/faf729b9c0>

To join the live webcast, please visit the "Investors and News" section of the Seres website at www.serestherapeutics.com.

A webcast replay will be available on the Seres website beginning approximately two hours after the event and will be archived for approximately 21 days.

About Seres Therapeutics

Seres Therapeutics, Inc. (Nasdaq: MCRB) is a commercial-stage company developing novel microbiome therapeutics for serious diseases. Seres' lead program, VOWST™, obtained U.S. FDA approval in April 2023 as the first orally administered microbiome therapeutic to prevent recurrence of *C. difficile* infection (CDI) in adults following antibacterial treatment for recurrent CDI and is being commercialized in collaboration with Nestlé Health Science. Seres is evaluating SER-155 in a Phase 1b study in patients receiving allogeneic hematopoietic stem cell transplantation. The Company is also conducting research to inform further development of microbiome therapeutics for ulcerative colitis. For more information, please visit www.serestherapeutics.com.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20231030359303/en/): <https://www.businesswire.com/news/home/20231030359303/en/>

Seres IR and PR Contact:

Kevin Mannix

kmannix@serestherapeutics.com

Source: Seres Therapeutics, Inc.